Recommended content

FDA’s new psychedelic guidance & hearing (Newsletter: July 14, 2026)

PA marijuana licensing bill; Congressional bill on cannabis/drug testing in hospitals advances; MA psychedelics vote; Hemp & marijuana op-ed

Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day.

Your support makes Marijuana Moment possible…

Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there.

Support our work at https://www.patreon.com/marijuanamoment

/ TOP THINGS TO KNOW

The Food and Drug Administration published a finalized version of guidance aimed at helping researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations—and has also scheduled a public hearing on the issue for September.

The House Energy and Commerce Subcommittee on Health approved a bill to require the Department of Health and Human Services to study how prevalent drug testing for marijuana, fentanyl and other drugs is in hospital emergency departments.

The Massachusetts House of Representatives passed an economic development bill that includes provisions to create a five-year pilot program allowing the

Read full article on Marijuana Moment

Follow us on Instagram or join us on facebook page

Be first to rate

Marijuana Moment
Source

More news